Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nornicotine in Smokeless Tobacco
NCT03998735Phase 1Active, not recruiting
- Sponsor
- Masonic Cancer Center
- Start
- Oct 2021
- Primary completion
- Aug 2025
- Countries
- 1
01
Overview
Phase 1, randomised trial (4 arms), sponsored by Masonic Cancer Center. Primary endpoint: Endogenous formation of NNN in smokeless tobacco users at 2 weeks. Started Oct 2021; status: active, not recruiting.
Beyond the preview
Go deeper on NCT03998735.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03998735.